Do antiretrovirals reduce the risk of non-AIDS-defining malignancies?

Current Opinion in HIV and AIDS

Volumn 4, Issue 1, 2009, Pages 42-51

  Silverberg, Michael J ^a   Abrams, Donald I ^b  

^a DIVISION OF RESEARCH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antiretroviral therapy; HIV; Immunodeficiency; Malignancy

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR; INDINAVIR; NELFINAVIR; PLACEBO; PROTEINASE INHIBITOR; RALTEGRAVIR; RITONAVIR; SAQUINAVIR; VICRIVIROC;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANUS CANCER; BREAST CANCER; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER RISK; CANCER SCREENING; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; COLORECTAL CANCER; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; KAPOSI SARCOMA; LIVER CANCER; LUNG CANCER; MEDICAL LITERATURE; OROPHARYNX CANCER; PRIORITY JOURNAL; REVIEW; RISK REDUCTION;

ANTI-RETROVIRAL AGENTS; BIOLOGICAL MARKERS; CD4 LYMPHOCYTE COUNT; CLINICAL TRIALS AS TOPIC; HIV INFECTIONS; HUMANS; IMMUNE TOLERANCE; IMMUNOLOGIC SURVEILLANCE; NEOPLASMS; RISK;

EID: 67849084535     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e32831a9875     Document Type: Review

References (73)

1. Silverberg MJ, Abrams DI. AIDS-defining and non-AIDS-defining malignancies: cancer occurrence in the antiretroviral therapy era. Curr Opin Oncol 2007; 19:446-451. (Pubitemid 47356600)
2. Clifford GM, Polesel J, Rickenbach M, et al. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst 2005; 97:425-432. (Pubitemid 40528605)
3. Herida M, Mary-Krause M, Kaphan R, et al. Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients. J Clin Oncol 2003; 21:3447-3453. (Pubitemid 46594077)
4. International Collaboration on HIV and Cancer. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst 2000; 92:1823-1830
5. Bedimo R, Chen RY, Accortt NA, et al. Trends in AIDS-defining and non-AIDS-defining malignancies among HIV-infected patients: 1989-2002. Clin Infect Dis 2004; 39:1380-1384.
6. Engels EA, Pfeiffer RM, Goedert JJ, et al. Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS 2006; 20:1645-1654.
7. Bower M, Powles T, Nelson M, et al. HIV-related lung cancer in the era of highly active antiretroviral therapy. AIDS 2003; 17:371-375. (Pubitemid 36230918)
8. Hessol NA, Seaberg EC, Preston-Martin S, et al. Cancer risk among participants in the Women's Interagency HIV Study. J Acquir Immune Defic Syndr 2004; 36:978-985. (Pubitemid 38949847)
9. Diamond C, Taylor TH, Aboumrad T, et al. Increased incidence of squamous cell anal cancer among men with AIDS in the era of highly active antiretroviral therapy. Sex Transm Dis 2005; 32:314-320. (Pubitemid 40578072)
10. Bahl S, Theis B, Nishri D, Marrett LD. Changing incidence of AIDS-related Kaposi sarcoma and non-Hodgkin lymphoma in Ontario, Canada. Cancer Causes Control 2008 [Epub ahead of print].
11. Biggar RJ, Chaturvedi AK, Goedert JJ, Engels EA. AIDS-related cancer and severity of immunosuppression in persons with AIDS. J Natl Cancer Inst 2007; 99:962-972.
12. Franceschi S, Maso LD, Rickenbach M, et al. Kaposi sarcoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. Br J Cancer 2008; 99:800-804.
13. Mocroft A, Kirk O, Clumeck N, et al. The changing pattern of Kaposi sarcoma in patients with HIV, 1994-2003: the EuroSIDA Study. Cancer 2004; 100:2644-2654.
14. Polesel J, Clifford GM, Rickenbach M, et al. Non-Hodgkin lymphoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. AIDS 2008; 22:301-306.
15. Shiels MS, Cole SR, Wegner S, et al. Effect of HAART on incident cancer and noncancer AIDS events among male HIV seroconverters. J Acquir Immune Defic Syndr 2008; 48:485-490.
16. Biggar RJ, Jaffe ES, Goedert JJ, et al. Hodgkin lymphoma and immunodefi- ciency in persons with HIV/AIDS. Blood 2006; 108:3786-3791.
17. Burgi A, Brodine S, Wegner S, et al. Incidence and risk factors for the occurrence of non-AIDS-defining cancers among human immunodeficiency virus-infected individuals. Cancer 2005; 104:1505-1511. (Pubitemid 41356166)
18. Kirk O, Pedersen C, Cozzi-Lepri A, et al. Non-Hodgkin lymphoma in HIVinfected patients in the era of highly active antiretroviral therapy. Blood 2001; 98:3406-3412.
19. Ledergerber B, Egger M, Erard V, et al. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. JAMA 1999; 282:2220-2226. (Pubitemid 30002965)
20. Mocroft A, Katlama C, Johnson AM, et al. AIDS across Europe, 1994-1998: the EuroSIDA study. Lancet 2000; 356:291-296.
21. Ferreros I, Lumbreras B, Hurtado I, et al. The shifting pattern of cause-specific mortality in a cohort of human immunodeficiency virus-infected and noninfected injecting drug users. Addiction 2008; 103:651-659. The above article is unique in that cause-specific mortality rates were compared in HIV-infected and HIV-uninfected injection drug users.
22. Patel P, Hanson DL, Sullivan PS, et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med 2008; 148:728-736. The above is a large cohort study evaluating risk factors and trends in cancer among HIV-infected patients and is one of few studies to evaluate NADM risk with respect to both calendar year and individual ART use.
23. Engels EA, Biggar RJ, Hall HI, et al. Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer 2008; 123:187-194. The above is one of few cancer registry match studies to include both reported HIV and AIDS cases. Also evaluated association of NADMs with AIDS diagnosis and CD4 T-cell counts.
24. Hessol NA, Pipkin S, Schwarcz S, et al. The impact of highly active antiretroviral therapy on non-AIDS-defining cancers among adults with AIDS. Am J Epidemiol 2007; 165:1143-1153. The above is one of few studies to evaluate NADM risk with respect to both calendar year and individual ART use. Also unique in that few other AIDS Cancer registry match studies include data on individual ART use. (Pubitemid 47233717)
25. Long JL, Engels EA, Moore RD, Gebo KA. Incidence and outcomes of malignancy in the HAART era in an urban cohort of HIV-infected individuals. AIDS 2008; 22:489-496. The above provides interesting analysis of NADM trends, clinical characteristics, and survival compared with patients with ADM.
26. Piketty C, Selinger-Leneman H, Grabar S, et al. Marked increase in the incidence of invasive anal cancer among HIV-infected patients despite treatment with combination antiretroviral therapy. AIDS 2008; 22:1203-1211. The above is the largest recent study to focus exclusively on anal cancer.
27. Chaturvedi AK, Pfeiffer RM, Chang L, et al. Elevated risk of lung cancer among people with AIDS. AIDS 2007; 21:207-213. The above is a large and well designed US-based AIDS and cancer registry match study of lung cancer. Indirect adjustment used to control for smoking. (Pubitemid 46036929)
28. Kirk GD, Merlo C, P OD, et al. HIV infection is associated with an increased risk for lung cancer, independent of smoking. Clin Infect Dis 2007; 45:103-110. Despite small numbers, provided comparison to HIV-uninfected injection drug users and had more complete adjustment for smoking compared with other studies. (Pubitemid 46984625)
29. Rimland D, Guest JL. Increasing incidence of prostate cancer in the Atlanta VA cohort study (HAVACS) [abstract]. In: 14th Conference on Retroviruses and Opportunistic Infections; 25-28 February 2007; Los Angeles, California; abstract 874. The above study evaluated both prostate cancer and prostate-specific antigen testing rates over time.
30. Crum-Cianflone N, Marconi V, Weintrob A, et al. Increased incidence of skin cancers among HIV-infected persons [abstract]. In: 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention; 22-25 July 2007; Sydney, Australia; abstract MOPEB086.
31. Crum-Cianflone N, Marconi V, Weintrob A, et al. Trends in AIDS-defining and non-AIDS-defining cancers among HIV-infected patients: a 20-year study [abstract]. In: 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention; 22-25 July 2007; Sydney, Australia, abstract MOPEB084.
32. Silverberg MJ, Neuhaus J, Bower M, et al. Risk of cancers during interrupted antiretroviral therapy in the SMART study. AIDS 2007; 21:1957-1963. This study has broad generalizability, given many countries involved, and is one of few randomized clinical trials to focus on incidence and risk factors for malignancies. (Pubitemid 47329772)
33. Bruyand M, Thiebaut R, Lawson-Ayayi S, et al. Immunodeficiency and risk of AIDS-defining and non-AIDS-defining cancers: ANRSCO3 Aquitaine Cohort, 1998 to 2006 [abstract]. In: 15th Conference on Retroviruses and Opportunistic Infections; 3-6 February 2008; Boston, Massachusetts: abstract 15. A novel evaluation of duration exposed to low CD4+ T-cell counts.
34. Crum-Cianflone N, Huppler Hullsiek K, Ganesan A, et al. The impact of nelfinavir on cancer development among HIV-infected persons [abstract]. In: 17th International AIDS Conference; 3-8 August 2008; Mexico City, Mexico: abstract THPE0232. One of few studies to evaluate individual antiretrovirals on cancer risk.
35. Serraino D, Piselli P, Busnach G, et al. Risk of cancer following immunosuppression in organ transplant recipients and in HIV-positive individuals in southern Europe. Eur J Cancer 2007; 43:2117-2123. Although much smaller in size compared with the Grulich et al. metaanalysis on same topic, this article provides a novel comparison of NADM risk in two immunosuppressed populations: patients with HIV and transplant recipients. (Pubitemid 47381577)
36. Steigbigel RT, Cooper DA, Kumar PN, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008; 359:339-354.
37. D'Souza G, Wiley DJ, Li X, et al. Incidence and epidemiology of anal cancer in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr 2008; 48:491-499. Small numbers, but one of few studies to include HIV-uninfected controls for study of anal cancer and provided comprehensive evaluation of risk factors including sexual behaviors and smoking.
38. Blum L, Pellet C, Agbalika F, et al. Complete remission of AIDS-related Kaposi's sarcoma associated with undetectable human herpesvirus-8 sequences during anti-HIV protease therapy. AIDS 1997; 11:1653-1655. (Pubitemid 27460259)
39. Cattelan AM, Calabro ML, Aversa SM, et al. Regression of AIDS-related Kaposi's sarcoma following antiretroviral therapy with protease inhibitors: biological correlates of clinical outcome. Eur J Cancer 1999; 35:1809-1815.
40. Cattelan AM, Calabro ML, Gasperini P, et al. Acquired immunodeficiency syndrome-related Kaposi's sarcoma regression after highly active antiretroviral therapy: biologic correlates of clinical outcome. J Natl Cancer Inst Monogr 2001; 28:44-49.
41. Conant MA, Opp KM, Poretz D, Mills RG. Reduction of Kaposi's sarcoma lesions following treatment of AIDS with ritonovir. AIDS 1997; 11:1300-1301.
42. Lebbe C, Blum L, Pellet C, et al. Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi's sarcoma. AIDS 1998; 12:F45-F49. (Pubitemid 28190688)
43. Murphy M, Armstrong D, Sepkowitz KA, et al. Regression of AIDS-related Kaposi's sarcoma following treatment with an HIV-1 protease inhibitor. AIDS 1997; 11:261-262. (Pubitemid 27055419)
44. Bower M, Fox P, Fife K, et al. Highly active antiretroviral therapy (HAART) prolongs time to treatment failure in Kaposi's sarcoma. AIDS 1999; 13:2105-2111. (Pubitemid 29509588)
45. Gill J, Bourboulia D, Wilkinson J, et al. Prospective study of the effects of antiretroviral therapy on Kaposi sarcoma-associated herpesvirus infection in patients with and without Kaposi sarcoma. J Acquir Immune Defic Syndr 2002; 31:384-390. (Pubitemid 35397090)
46. Wolf T, Brodt HR, Fichtlscherer S, et al. Changing incidence and prognostic factors of survival in AIDS-related non-Hodgkin's lymphoma in the era of highly active antiretroviral therapy (HAART). Leuk Lymphoma 2005; 46:207-215. (Pubitemid 40185950)
47. Pati S, Pelser CB, Dufraine J, et al. Antitumorigenic effects of HIV protease inhibitor ritonavir: inhibition of Kaposi sarcoma. Blood 2002; 99:3771-3779. (Pubitemid 34534550)
48. Sgadari C, Barillari G, Toschi E, et al. HIV protease inhibitors are potent antiangiogenic molecules and promote regression of Kaposi sarcoma. Nat Med 2002; 8:225-232. (Pubitemid 34250099)
49. Sgadari C, Monini P, Barillari G, Ensoli B. Use of HIV protease inhibitors to block Kaposi's sarcoma and tumour growth. Lancet Oncol 2003; 4:537-547. (Pubitemid 38351710)
50. Ikezoe T, Hisatake Y, Takeuchi T, et al. HIV-1 protease inhibitor, ritonavir: a potent inhibitor of CYP3A4, enhanced the anticancer effects of docetaxel in androgen-independent prostate cancer cells in vitro and in vivo. Cancer Res 2004; 64:7426-7431. (Pubitemid 39372084)
51. Pajonk F, Himmelsbach J, Riess K, et al. The human immunodeficiency virus (HIV)-1 protease inhibitor saquinavir inhibits proteasome function and causes apoptosis and radiosensitization in non-HIV-associated human cancer cells. Cancer Res 2002; 62:5230-5235. (Pubitemid 35024595)
52. Gills JJ, Lopiccolo J, Tsurutani J, et al. Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo. Clin Cancer Res 2007; 13:5183-5194. (Pubitemid 47502088)
53. Gupta AK, Li B, Cerniglia GJ, et al. The HIV protease inhibitor nelfinavir downregulates Akt phosphorylation by inhibiting proteasomal activity and inducing the unfolded protein response. Neoplasia 2007; 9:271-278. (Pubitemid 46608294)
54. Pyrko P, Kardosh A, Wang W, et al. HIV-1 protease inhibitors nelfinavir and atazanavir induce malignant glioma death by triggering endoplasmic reticulum stress. Cancer Res 2007; 67:10920-10928. (Pubitemid 350145921)
55. Valdes F, Chow WA. The HIV protease inhibitor Nelfinavir inhibits human SW872 liposarcoma clonogenicity by inducing apoptosis and is associated with an increase in levels of SREBP-1 [abstract]. In: 95th Annual Meeting of the American Association for Cancer Research; 27-31 March 2004; Orlando, Florida: abstract 535.
56. Brunner TB, Geiger M, Grabenbauer GG, et al. Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer. J Clin Oncol 2008; 26:2699-2706.
57. Gulick RM, Su Z, Flexner C, et al. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211. J Infect Dis 2007; 196:304-312. (Pubitemid 47047471)
58. Gulick R, Su Z, Flexner C, et al. ACTG 5211: phase II study of the safety and efficacy of vicriviroc (VCV) in HIV-infected treatment experienced subjects: 48 week results [abstract]. In: 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention; 22-25 July 2007; Sydney, Australia: abstract TUAB102.
59. Saag M, Ive P, Heera J, et al. A multicenter, randomized, double-blind, comparative trial of a novel CCR5 antagonist, maraviroc versus efavirenz, both in combination with combivir (zidovudine [ZDV]/lamivudine [3TC]), for the treatment of antiretroviral naive patients infected with R5 HIV 1: week 48 results of the MERIT study [abstract]. In: 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention; 22-25 July 2007; Sydney, Australia: abstract WESS104.
60. Frisch M, Biggar RJ, Engels EA, Goedert JJ. Association of cancer with AIDSrelated immunosuppression in adults. JAMA 2001; 285:1736-1745. (Pubitemid 32259908)
61. Goedert JJ, Cote TR, Virgo P, et al. Spectrum of AIDS-associated malignant disorders. Lancet 1998; 351:1833-1839.
62. Grulich AE, Wan X, Law MG, et al. Risk of cancer in people with AIDS. AIDS 1999; 13:839-843.
63. Grulich AE, Li Y, McDonald A, et al. Rates of non-AIDS-defining cancers in people with HIV infection before and after AIDS diagnosis. AIDS 2002; 16:1155-1161. (Pubitemid 34533854)
64. Engels EA, Brock MV, Chen J, et al. Elevated incidence of lung cancer among HIV-infected individuals. J Clin Oncol 2006; 24:1383-1388. (Pubitemid 46622002)
65. Mbulaiteye SM, Biggar RJ, Goedert JJ, Engels EA. Immune deficiency and risk for malignancy among persons with AIDS. J Acquir Immune Defic Syndr 2003; 32:527-533. (Pubitemid 36423125)
66. Phelps RM, Smith DK, Heilig CM, et al. Cancer incidence in women with or at risk for HIV. Int J Cancer 2001; 94:753-757. (Pubitemid 33035698)
67. Biggar RJ, Kirby KA, Atkinson J, et al. Cancer risk in elderly persons with HIV/AIDS. J Acquir Immune Defic Syndr 2004; 36:861-868. (Pubitemid 38859353)
68. Marin B, Thiébaut R, Rondeau V, et al. Association between CD4 and HIV RNA with non AIDS-related causes of death in the era of combination antiretroviral therapy (cART) [abstract]. In: 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention; 22-25 July 2007; Sydney, Australia: abstract WEPEB019. Using data from Concerted Action on Seroconversion to AIDS and Death in Europe (CASCADE), this is the largest study to date on topic among patients with known duration of HIV infection.
69. Baker JV, Peng G, Rapkin J, et al. CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection. AIDS 2008; 22:841-848. One of few randomized clinical trials to focus on malignancies and provides a comprehensive overview of association between immunodeficiency and fatal malignancies and other fatal non-AIDS conditions. (Pubitemid 351563833)
70. Monforte AD, Abrams D, Pradier C, et al. HIV-induced immunodeficiency and risk of fatal AIDS-defining and non-AIDS-defining malignancies: results fromthe D:A:D study [abstract]. In: 14th Conference on Retroviruses and Opportunistic Infections; 25-28 February 2007; Los Angeles, California: abstract 84. An excellent description of association of immunodeficiency and risk of fatal malignancies and risk factors for ADMs and NADMs.
71. Bedimo R, Dunlap M, McGinnis K, et al. Trends in incidence of non- AIDS-defining malignancies in HIV-infected vs. noninfected veterans in the HAART era: impact of immunosuppression [abstract]. In: 17th International AIDS Conference; 3-8 August 2008; Mexico City, Mexico: abstract MOPE0243. A large cohort study and one of few studies to include HIV-uninfected persons from same population (i.e., US Veterans).
72. Nowicki MJ, Vigen C, Mack WJ, et al. Association of cells with natural killer (NK) and NKT immunophenotype with incident cancers in HIV-infected women. AIDS Res Hum Retroviruses 2008; 24:163-168. The only recent study to evaluate innate immunity in relation to cancer risk in HIV patients. (Pubitemid 351282096)
73. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007; 370:59-67. A large metaanalysis providing novel comparison of NADM risk in two immunosuppressed populations: patients with HIV or AIDS and transplant recipients.